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Pertussis is a respiratory infection caused by Bordetella pertussis that may be particu-
larly severe and even lethal in the first months of life when infants are still too young to 
be vaccinated. Adults and adolescents experience mild symptoms and are the source 
of infection for neonates. Adoptive maternal immunity does not prevent pertussis in the 
neonate. We compared the specific immune response of mothers of neonates diagnosed 
with pertussis and mothers of control children. We show that women have pre-existing 
pertussis-specific antibodies and memory B cells and react against the infection with 
a recall response increasing the levels specific serum IgG, milk IgA, and the frequency 
of memory B cells of all isotypes. Thus, the maternal immune system is activated in 
response to pertussis and effectively prevents the disease indicating that the low levels 
of pre-formed serum antibodies are insufficient for protection. For this reason, memory 
B cells play a major role in the adult defense. The results of this study suggest that new 
strategies for vaccine design should aim at increasing long-lived plasma cells and their 
antibodies.
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INTRODUCTION
Mammalians protect their progeny during the first days and months of life through the adoptive 
transfer of maternal antibodies. At birth, the still immature immune system of the newborn faces 
the challenge of encountering thousands of different commensal and pathogenic microorganisms, 
which rapidly colonize its body surfaces and mucosal epithelia. In this phase, the adoptive transfer 
of the maternal immune experience helps the newborn to survive and generate its own immune 
defenses (1). Before birth, the mother transfers to the fetus her systemic memory, represented by 
serum IgG, which will protect the child during the first months of life, although rapidly decaying 
between three and six months of age (2). After birth, the neonate can only receive the mucosal 
immune memory of the mother through the IgA antibodies transferred with the breast milk. 
Human milk not only contains all the nutrients and vitamins needed for neonatal growth and 
2Marcellini et al. Pertussis Infection and Memory B Cells
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1158
development, but it is also rich of substances with anti-infective 
activity, which protect the neonate from the microorganisms 
colonizing the respiratory ways and gut immediately after birth 
(3, 4). Whereas cytokines, defensins, and lactoferrin, produced 
by the innate immune system of the mother, exert a wide-range 
protection, secretory IgA defend the child only from pathogens 
known by the immune system of the mother (5). Milk IgA 
derives from plasma cells that migrate from mucosal sites to the 
mammary gland at the end of pregnancy and during lactation. 
Migration is driven by chemokines and mediated by adhesion 
molecules (6, 7). Gut IgA is generated by T-cell-dependent (TD) 
and -independent mechanisms (8). Most commensal bacterial 
species are coated by polyreactive T-cell-independent natural 
IgA. Natural IgA has the additional function of favoring bacte-
rial uptake by Peyer patches where the TD adaptive immune 
response generates highly specific IgA. Similar to natural IgA at 
mucosal sites, natural IgM in the serum has not only the func-
tion of first-line defense against infection but also the function 
of trapping antigen into complexes that are rapidly delivered to 
follicular dendritic cells to initiate and maintain the germinal 
center (GC) reaction. Natural IgM in the serum is produced by 
IgM memory B cells. IgM memory B cells, also called “natural/
natural effector” or innate memory B  cells, can be found in 
patients unable to form GCs (9–11), suggesting that they have 
a T-cell-independent origin (12–14). The other type of memory 
B  cells in the peripheral blood, switched memory B  cells, is 
generated by TD adaptive immune responses in the GC (14). 
One-third of the switch memory B cells express IgA, and the rest 
are of IgG isotype. IgA and IgG switched memory B carry many 
somatic mutations (SM) and are highly specific. We have recently 
shown that innate memory B cells revise their B-cell receptor in 
the GC acquiring SM and becoming remodeled IgM memory 
B cells (14).
Vaccinations, similar to natural infections, trigger the GC reac-
tion resulting in the generation of two cell types, both expressing 
high-affinity antibodies: long-lived memory plasma cells and 
switched memory B  cells. Memory plasma cells continuously 
secrete their antibodies thus ensuring the presence of pre-formed 
specific antibodies in the serum. Memory B cells instead are the 
main actors of the recall response. They rapidly react to a renewed 
antigen encounter with proliferation and plasma cells formation 
to increase the concentration of specific antibodies and prevent 
re-infection and disease (15).
In order to study the in vivo response to infection, we analyzed 
peripheral blood, serum, and breast milk of women exposed to 
pertussis infection.
Pertussis is a respiratory infection caused by Bordetella 
pertussis that may be particularly severe and even lethal in the 
first months of life especially when infants are still too young to 
be vaccinated. Breast feeding protects the neonate from several 
respiratory and gastro-enteric pathogens, as demonstrated by the 
observation that the mortality rate due to infection is reduced 
by half in neonates receiving maternal milk (5, 16). Based on the 
results of a case–control study, however, we have recently demon-
strated that breast feeding does not protect infants from pertussis 
(17). In addition, we have shown that mothers may represent the 
source of infection for children in 50% of the cases (18).
In order to understand why the maternal immune system is 
unable to prevent neonatal pertussis infection, we conducted a 
study on the mothers of infants (<6 months) diagnosed with 
pertussis and compared them to two groups of controls. The first 
group included mothers of healthy infants admitted as outpa-
tients for hip ultrasound screening [healthy controls (HCs)] and 
the second mothers of children hospitalized for lower respiratory 
tract infections (LRTI) other than pertussis.
We found that mothers that are not infected or exposed to 
pertussis (HC and LRTI) have low levels of pertussis-specific 
antibodies in the serum and breast milk and are therefore unable 
to transfer passive protection to their children before or after 
birth. Mothers of children with pertussis actively protect them-
selves from the ongoing infection by increasing the number of 
specific memory B cells that secrete IgG and IgA and producing 
anti-pertussis toxin IgG and IgA antibodies in the serum.
IgM memory B cells secreting antibodies able to react with 
pertussis antigens and Bordetella-binding milk IgA increase, not 
only in mothers of children with pertussis but also in the mothers 
of neonates with LRTI. Thus, whereas switched memory B cells 
and serum IgA and IgG increase specifically in response to per-
tussis, IgM memory B cells and milk IgA are aspecifically induced 
during infection generating a wide spectrum antibody response.
PATIENTS AND METHODS
Study Population
In this study, we included the mothers of infants enrolled in a 
case–control investigation conducted between June 2012 and 
January 2015 in two Italian large metropolitan pediatric hospitals, 
located in Rome, Italy. Part of the results of this study was pub-
lished before (17). Mothers included in the study were mothers 
of unvaccinated children, younger than 6 months, hospitalized 
for pertussis, diagnosed by real-time polymerase chain reaction. 
Mothers of two groups of controls aged <6 months were enrolled 
including healthy infants admitted as outpatients for hip ultra-
sound screening at one of the participating hospitals or infants 
hospitalized because of low tract respiratory infections other than 
pertussis, in the same period during which cases were recruited. 
Mothers of enrolled children were requested to undergo a whole 
blood and serum sample collection and to donate a sample of 
breast milk.
Information on the medical histories of the eligible parents 
was collected onto standard report forms. Data were collected 
through a questionnaire administered to parents of patients (per-
tussis, LRTI and HC) at enrollment, after signing an informed 
consent.
Epidemiological, microbiological, and immunological data 
were recorded in a unique electronic database. The median age 
of mothers was 34.6 years (range 18.4–46.4). Among these, 15% 
were smokers, 33% were graduates, and 65% had a job. None had 
been vaccinated against pertussis and no one remembered having 
had the disease.
The study was approved by the Bambino Gesù Children’s 
Hospital Ethical Committee (protocol no RF-2010-2317709). 
Informed consent was signed from mothers of children and the 
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study was performed following the guidelines of the Declaration 
of Helsinki.
Samples
Sociodemografic, clinical, and microbiological data of children 
and families included in the study were published elsewhere 
(17). Only mothers who were breast feeding were included in 
the immunological study. We collected blood samples from 
61 HC mothers (HC), 36 mothers of children with LRTI other 
than pertussis (LRTI) and 57 mothers of children with pertussis 
(PERTUSSIS). Milk was obtained from 61 HC, 21 LRTI, and 53 
PERTUSSIS women. Serum anti-PT levels were available for 50 
of the HC, 17 of the LRTI, and 57 of the PERTUSSIS mothers 
included in the immunological study.
None of the enrolled mothers had been vaccinated against 
pertussis or recalled to have had the disease.
Analysis of Breast Milk
Whole-milk aliquots were stored at −20°C in a frost-free freezer, 
until assayed for pertussis-specific antibodies.
Bacteria Preparation for Live Bacterial 
FACS
Bacterial isolates were cultured on Columbia agar + 5% sheep 
blood for 24  h at 37°C, morphologically characterized and 
subsequently identified with matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry.
Bordetella pertussis isolated from nasopharyngeal aspirates 
was stored at −80°C, using a system of small glass spheres in a 
test tube from freezing Cryobank (Mast Diagnostics GmbH).
To obtain viable bacteria, a sphere with adherent bacteria 
was removed from the frozen test tube using a sterile needle and 
immediately placed on Bordetella Selective Agar (Biolife Italian 
Srl, Italy), where the bead was streaked on the surface of the soil 
to distribute the bacterial cells and incubated at 35°C in a humid 
atmosphere for approximately 4–5 days.
Bacterial colonies were collected using a sterile swab and 
mixed in a test tube with a sterile saline solution of NaCl 0.45% 
(Bio Merieux S.A.) to obtain a suspension of 3 McFarland.
Live Bacterial FACS
The study included B. pertussis and other seven frozen barcoded 
bacterial isolates from routine specimens (Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Streptococcus pneumoniae, Strepto-
coccus salivarius, Staphylococccus aureus, Enterococcus faecalis, 
and Escherichia coli).
Bacterial single colonies and B. pertussis suspension were 
diluted in 1.5  μL PBS. For each staining, 45  μL of bacteria 
suspension was incubated with either FACS buffer (PBS + FBS 
2% +  sodium azide 0.1%) (negative control) or maternal milk 
(5 μL of 1:10, 1:100 dilution in FACS buffer) and left for 20 min on 
ice. Samples were washed three times with ice-cold FACS buffer 
and then anti-human IgA-fitc-labeled was added for 20 min. 
After three washing steps, bacteria were diluted in 300 μL ice-
cold FACS buffer and data was acquired on a FACS Canto II (BD 
Bioscience) using FCS and SSC parameters in logarithmic mode 
(Figures S1A,B in Supplementary Material). Data were analyzed 
using the DIVA 6.0 software (BD Bioscience).
The binding of human IgA to bacteria (bacterial binding) 
was measured by comparing the staining for IgA of each bacte-
rial species incubated either with FACS buffer or with milk. 
The frequency of bacterial binding is a semi-quantitative meas-
ure of the concentration of specific antibody in the analyzed 
sample.
ELISA
Pertussis toxin-specific IgG (PT-IgG) was measured in sera 
of mothers using the ELISA standardized within a European 
Sero-Epidemiology Network (19, 20) as detailed elsewhere (21). 
In-house reference sera and international standards (06/142, 
WHO International Standard Pertussis Antiserum) were 
calibrated against the USA-FDA standard serum (lot 3-HRP3) 
(22). The results were expressed in international units (IU)/mL. 
The limit of detection of the assay was 1 IU/mL. Pertussis toxin-
specific IgA (PT-IgA) was measured in sera using a commercial 
ELISA kit (Anti-Bordetella Pertussis Toxin IgA, Euroimmun AG) 
according to the manufacturer’s instruction. Data are expressed 
in IU/mL, and the lower detection limit was 0.7 IU/mL.
Pertussis toxin-specific IgM (PT-IgM) was measured in sera 
using an in-house ELISA. Briefly, Immulon® Microtiter™ 96-Well 
Plates (Termofisher) coated with 200 ng of purified PT antigen 
(21) were incubated with 100 mL/well of 1:100 prediluted sera 
for 2 h at 28°C. After washing, peroxidase-conjugate anti-human 
IgM Ab (Jackson Immuno Research Laboratories) was added 
to the wells and plates incubated O.N. at RT. After incubation, 
the plates were washed and the substrate solution added (OPD; 
Sigma-Aldrich). The reaction was stopped after 20 min by the 
addition of 10% sodium dodecyl sulfate, and plates were read at 
450 nm wavelength. Since no specific international standards for 
PT-IgM are available, optical density (OD) values are reported.
Cell Isolation and Flow Cytometry B Cells 
Phenotype
Heparinized peripheral blood mononuclear cells (PBMCs) 
were isolated by Ficoll Paque™ Plus (Amersham Pharmacia 
Biotech) density-gradient centrifugation, counted, and stained 
with the appropriate combination of fluorescent labeled with 
anti-CD19, anti-CD27, anti-CD24, and anti-IgM antibodies and 
analyzed by flow cytometry. We calculated, in the lymphocyte 
gate, the frequency of total B (CD19+) and memory B  cells 
(CD19+CD24+CD27+). We also measured the frequency of IgM 
(CD19+CD24+CD27+Ig+) and switched (CD19+CD24+CD27+
IgM−) memory B cells in the memory B cells gate. For each stain-
ing, at least 50,000 events in the lymphocyte gate were collected 
on a FACS Canto II. Data were analyzed using the DIVA 6.0 
software (BD Bioscience).
CpG Stimulation and ELISPOT
Peripheral blood mononuclear cells were cultured in complete 
medium at a concentration of 2.5 × 106 cells/mL. A total of 0.35 µM 
CpG B ODN2006 (Hycult Biotech) was added to stimulate the 
proliferation and differentiation of memory B cells for 5 days.
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Ninety-six-well plates (MultiScreen-HA, Milipore) were 
coated overnight with AffiniPure F(ab′)2 Fragment Goat anti- 
human IgA+IgG+IgM (H  +  L; Jackson Immuno Research 
Laboratories) for the measurement of total memory B cells. For 
the detection of specific memory B cells, plates were coated with 
B. pertussis antigens (5  µg/mL): purified PT (NIBSC, Potters 
Bar, UK), filamentous hemagglutinin (FHA) (NIBSC, Potters 
Bar, UK), and pertactin (PRN) (List Biological Labs, Campbell, 
CA). After washing with sterile PBS/0.05% Tween 20, plates were 
blocked for 1 h at 37°C with PBS/gelatin 1%.
Peripheral blood mononuclear cells stimulated for 5  days, 
as described before, were collected, counted, and seeded in the 
pre-coated plates. Plates were left at 37°C, 2% CO2 for 4–6 h to 
allow antibody secretion. A total of three 1:2 serial dilutions were 
done starting in the first well with 5 × 104 cells for detection of 
total IgM, IgG, and IgA. A total of 2 × 105 cells were seeded in the 
first dilution well (three 1:2 serial dilutions) for the detection of 
B cells secreting specific antibodies. After incubation, plates were 
washed with dH2O/0.05% Tween 20 (once) and PBS/0.05% Tween 
20 (two times) and incubated overnight with either anti-IgM 
HRPO (1:1,000), anti-IgG HRPO (1:2,000), or anti-IgA (1:2,000; 
Jackson Immuno Research Laboratories) diluted in PBS + gelatin 
(1 + 0.05%) Tween 20 (Sigma). After washing twice as before, 
TMB substrate (ready to use from Mabtech) was used accord-
ing to the manufacturer’s instructions. Plates were left at room 
temperature to allow the blue color to develop and the reaction 
was stopped with dH2O. Plates were left to dry before counting 
with an ELISCAN (A-EL-VIS).
Statistical Analysis
Data are presented as median (interquartile range). Mann–
Whitney U test was used to compare all data because of distri-
bution. Pearson correlation coefficient was used to measure the 
linear correlation between samples. GraphPad Prism software 
(CA, USA) was used for statistical analysis. A p-value of less than 
0.05 was considered as statistically significant.
RESULTS
Serum Antibodies
PT is a highly antigenic and specific component of B. pertussis 
(23). Anti-PT-IgG ≥ 100 IU/mL is used as specific indicator of 
recent pertussis infection (18).
We measured IgG antibodies directed against PT in the 
serum of mothers of HC, LRTI, and PERTUSSIS infants by 
ELISA. IgG antibodies were present at significantly lower con-
centration in HC [13.45 (8.32–38.15) p ≤ 0.0001] and LRTI [14 
(11–36) p = 0.002] mothers than in PERTUSSIS mothers [63.5 
(16.75–158.3)] (Figure 1A).
Anti-PT-IgA concentration increases during B. pertussis infec-
tion but decays more rapidly compared to IgG. Cutoff value of 
20 IU/mL is indicative of a recent pertussis infection (Prospective 
Evaluation of an Australian Pertussis Toxin IgG and IgA Enzyme 
Immunoassay). IgA against PT significantly increased in 
PERTUSSIS [5.5 (0–39.5)] mothers compared to HC [0 (0–0) 
p = 0.005] and LRTI [0 (0–0) p = 0.01] mothers (Figure 1B). 
There was a positive correlation between the concentration of IgG 
and IgA in the PERTUSSIS mothers (Pearson r = 0.4, p = 0.03).
In Figure 1C, we show that in the PERTUSSIS group, mothers 
with anti-PT-IgG ≥ 100 IU/mL had significantly higher level of 
anti-PT-IgA than mothers with anti-PT-IgG < 100 IU/mL, indi-
cating an ongoing specific immune response against B. pertussis 
infection.
Anti-PT-IgM is not usually included in the tests for the 
diagnosis of pertussis, and no international standard is 
available. We performed an in-house ELISA using coated 
plates with purified PT antigen. We used OD values as a 
measure of IgM concentration. We found that anti-PT-IgM 
was increased not only in the serum of PERTUSSIS (p = 0.02) 
but also in the serum of LRTI mothers when we compared 
them to HC mothers (Figure  1D) indicating an aspecific 
increase in IgM during infection. Only one mother of the 
PERTUSSIS group had high IgM OD value, probably reflect-
ing a primary immune response (IgG levels were 94 IU/mL 
in this individual).
In our study, we were not able to measure the variation of 
anti-PT-IgG titers before and after pertussis exposure in the same 
subject. We could only compare individual values of mothers 
of HC neonates and of children diagnosed with PERTUSSIS 
(Figure 1).
No correlate of protection has been established for pertussis, 
but anti-PT-IgG levels >5 IU/mL has been considered potentially 
protective (24). Eighty-four percent of HC mothers had antibody 
levels >5 IU/mL. As none of the mothers had ever been vacci-
nated against pertussis, or remembered to have had pertussis in 
the past, serum anti-PT-IgG can be considered as an indication of 
a previous undiagnosed infection. A significant increase in anti-
PT-IgG was observed in the PERTUSSIS mothers demonstrating 
that the immune system is activated even in the presence of pre-
formed antibodies (Figure 1).
The increase in IgG in the serum of mothers of PERTUSSIS 
group could be explained by the function of pre-existing memory 
B cells rapidly producing antibodies in response to bacterial chal-
lenge, thus performing a classical recall response.
B-Cell Phenotype and Total Memory  
B Cells
We compared the peripheral blood B-cell compartment of HC, 
LRTI, and PERTUSSIS mothers. There was no difference in the 
frequency of total B cells and memory B cells between the three 
groups (Figure 2A). In the memory pool, whereas PERTUSSIS 
and LRTI mothers had equal frequencies of IgM and switched 
memory B cells, IgM memory B cells were significantly more than 
switched memory B cells (p = 0.014) in HC mothers (Figure 2A).
The number of memory B cells in the peripheral blood can 
be determined also based on their ability to secrete antibodies, 
by ELISPOT. We stimulated PBMCs from mothers of control 
(HC and LRTI) and pertussis children with the TLR9 ligand CpG 
in order to induce the proliferation of memory B cells and their 
differentiation into antibody-producing cells (12, 25). We found 
comparable frequencies of memory B cells secreting IgM−IgA− 
or IgG in HC, LRTI, and PERTUSSIS mothers (Figure 2B).
FIGURE 1 | Anti-PT-specific Ig in the serum. (A,B) The plot shows the concentration of specific anti- pertussis toxin-specific IgG (PT-IgG) or pertussis toxin-specific 
IgA (PT-IgA) in the serum of control [healthy controls (HC) and lower respiratory tract infections (LRTI)] and PERTUSSIS mothers. (C) The plot shows the 
concentration of specific anti-PT-IgA in the serum of PERTUSSIS mothers with anti-PT-IgG ≥ 100 IU/mL or with anti-PT-IgG < 100 IU/mL. (D) Optical density value 
of IgM in the serum of control (HC and LRTI) and PERTUSSIS mothers. Statistical significance was determined using the Mann–Whitney test; *p < 0.05, **p < 0.01, 
and ***p < 0.001. A total of 50 HC, 17 LRTI, and 57 PERTUSSIS samples could be evaluated for IgG. A total of 15 HC, 15 LRTI, and 20 PERTUSSIS samples could 
be evaluated for IgA and IgM.
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Memory B Cells Secreting Specific  
Anti-Pertussis IgM, IgA, and IgG
We measured the frequency of memory B cells in the peripheral 
blood by ELISPOT against three different pertussis antigens 
(PT, FHA, and PRN). The number of antigen-specific spots was 
divided by the total number of total IgG spots in order to calculate 
the frequency of specific spots in the total pool of memory B cells.
Pertussis-specific switched memory B  cells changed in 
response to infection. In the PERTUSSIS mothers, the number 
of B  cells producing IgG against the three different antigens 
significantly increased compared to HC and LRTI mothers. No 
increase in memory B  cells producing IgG against B. pertussis 
was observed in the LRTI group (Figure 3A, plots and Mann–
Whitney U statistics).
We also measured serum IgA, because IgA is the major 
immunoglobulin produced in the respiratory tract at the site of 
B. pertussis invasion (26). We observed a significant increase in 
the frequency of the IgA spots against the three pertussis antigen 
between HC and PERTUSSIS mother (PT p  =  0.0005; FHA 
p = 0.0003; PRN p = 0.001). Memory B cells secreting IgA against 
PRN were slightly increased in the mothers of children with LRTI 
(Figure 3B).
Thus, mothers of neonates hospitalized because of pertussis 
were actively protecting themselves against the pathogen by 
increasing the frequency of specific memory B cells.
As previously observed for other bacterial antigens, the 
frequency of IgM spots is higher than those of IgA and IgG 
isotype (27). B cells producing IgM against pertussis increased 
significantly between HC and PERTUSSIS mothers (PT and PRN 
p ≤ 0.0001; FHA p = 0.0002), but, in contrast to switched memory 
B cells, IgM memory B cells able to bind pertussis antigens also 
increased significantly in mothers of children with LRTI (PT 
p = 0.002; FHA p = 0.004; PRN p = 0.03) (Figure 3C). Thus, dur-
ing respiratory infections (LRTI and PERTUSSIS), IgM increases 
non-specifically.
FIGURE 2 | Peripheral B-cell subset analysis. (A) Frequency (%) of B cells (defined as CD19+), total memory B cells (CD19+CD27+), IgM (CD19+CD27+IgM+), and 
switched (CD19+CD27+IgM−) memory B cells is depicted for healthy controls (HC), lower respiratory tract infections (LRTI), and PERTUSSIS mothers. The staining 
was performed using antibodies anti-CD19, -CD24, -CD27, and -IgM. (B) A number of total IgM, IgA, and IgG spots per million of total peripheral blood 
mononuclear cells are shown both for control (HC and lower respiratory tract infections) and PERTUSSIS mothers. A total of 61 HC, 36 LRTI and 47 PERTUSSIS 
mothers were compared. Mann–Whitney statistical test was used for calculation of the reported p-value. Statistical significance is marked as *p < 0.05.
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IgA in the Milk
After birth, the neonate can only receive the mucosal immune 
memory of the mother through the IgA antibodies transferred 
with breast milk. We detected the abundance of IgA react-
ing with eight different bacteria (B. pertussis, S. pneumoniae, 
K. pneumoniae, Escherichia coli, Enterococcus faecalis, Streptococcus 
salivarius, Staphylococcus aureus, and Pseudomonas aeruginosa) 
in breast milk of HC, LRTI, and PERTUSSIS. We measured the 
ability of milk IgA to react with fresh bacteria using the bacterial 
FACS technique (Figures S1A,B in Supplementary Material). We 
observed that breast milk of HC, LRTI and PERTUSSIS moth-
ers contains IgA able to react with different commensal and 
pathogenic microorganisms that can be found in the microbial 
communities colonizing airways, gut, and skin. IgA reacting with 
B. pertussis was present in low amounts compared to IgA against 
other bacterial species (Figure S1C in Supplementary Material). 
In the milk of PERTUSSIS mothers IgA antibodies reacting with 
B. pertussis were significantly increased compared to HC mothers 
(p = 0.001) (Figure 4). IgA anti-pertussis was also increased in 
LRTI mothers (p = 0.003). In this group, also IgA directed to 
S. pneumoniae was significantly higher than in HC or PERTUSSIS 
mothers (Figure 4). No significant difference was found in the 
amount of antibodies binding other bacterial species between the 
milk of the three groups (Figure 4).
DISCUSSION
Pertussis is a severe and even lethal disease for children too young 
to be vaccinated. It has been shown that in the majority of the cases 
neonates are infected by their mothers or by household members. 
Awareness among physicians about pertussis circulation has led 
to increased suspect of the disease in patients with persistent 
coughing and, consequently, to a more frequent testing. It has 
been shown that B. pertussis infects subjects of all ages who act 
as infection source causing local clusters of disease (28). Adults 
and adolescents may be unaware of being infected by B. pertussis 
as they experience mild symptoms, difficult to distinguish from 
those caused by other respiratory infections. Mothers included in 
our study had never been vaccinated and did not recall a previous 
pertussis infection. Based on the high concentration of anti-PT-
IgG in the serum, we have hypothesized that they were the source 
of infection for their children in at least 50% of the cases (18). 
We now show that, although symptoms were modest or absent, 
the immune system of the PERTUSSIS mothers actively reacted 
against the pathogen by expanding antigen-specific memory 
B  cells and thereby increasing the production of antibodies of 
IgG and IgA isotype. Thus, we hypothesize that, in the adult, spe-
cific memory B cells prevent severe clinical pertussis by rapidly 
producing antibodies. The detectable baseline levels of antibodies 
FIGURE 3 | Memory B cells specific for pertussis antigens. (A,B,C) Number of specific anti-PT (toxin [PT], filamentous hemagglutinin [FHA], and pertactin 
[PRN])-IgG, -IgA, and -IgM spots per million of total cultured peripheral blood mononuclear cells are shown in healthy controls (n = 61), lower respiratory tract 
infections (n = 36), and PERTUSSIS (n = 47) mothers. Statistical significance was determined using the Mann–Whitney test; *p < 0.05, **p < 0.01, and 
***p < 0.001.
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and memory B cells in control mothers (HC and LRTI) and the 
ability to generate a recall response, demonstrated in PERTUSSIS 
mothers, indicate that previous contacts with B. pertussis have 
occurred in the adult population. These subclinical contacts gen-
erated an immune memory that is sufficient to prevent a severe 
disease but not to avoid colonization, disease, and transmission.
Serum antibodies are excellent correlates of protection for 
many infectious diseases (29) but for pertussis there is no “uni-
versally accepted quantifiable serological measure of protection” 
(30). We show that the recall response of memory B cells is used 
by the adult immune system for protection.
Maternal vaccination prevents neonatal pertussis. Retrospec-
tive studies showed 91% effectiveness of DTaP vaccination of 
mothers for protecting newborns against pertussis in the first 
2 months of life (31, 32). Cocoon strategies involving the vac-
cination of both parents immediately after the delivery are instead 
unable to prevent pertussis in the neonate (33, 34). As the mother 
can exclusively transfer antibodies and no memory B cells during 
pregnancy, the effectiveness of maternal vaccination indicates 
that passively transferred IgG indeed protect against infection, 
but only at high concentrations. Placental transfer of anti-PT 
maternal antibodies is a highly efficient mechanism ensuring that 
specific IgG levels are higher in the newborn than in the mother 
(23). Transferred antibodies rapidly decay and at 2 months of age 
the concentration of anti-PT-IgG is decreased by 76% from the 
levels measured in cord blood (24).
After birth, the immune system of the mother can still con-
tribute to the protection of the neonate through IgA antibodies in 
the milk. In breast milk, we find IgA antibodies binding bacterial 
species that are members of the microbial communities of the res-
piratory and intestinal mucosa and of the skin. IgA able to react 
with pertussis is present at low concentrations in breast milk of 
women not exposed to the infection and increased in mothers of 
the PERTUSSIS group. Thus, the low levels of B. pertussis-specific 
antibodies, in the serum and in the milk, explain why neonates 
are born without suffi
FIGURE 4 | IgA in breast milk reacts with several bacterial species. Graphs show the frequency of bacteria of the indicated species binding to IgA contained in the 
milk (1:10 dilution) of healthy controls (HC), lower respiratory tract infections (LRTI), and PERTUSSIS mothers. The difference between groups was determined using 
the Mann–Whitney test; **p < 0.01 and ***p < 0.001. Milk from 61 HC, 21 LRTI, and 53 PERTUSSIS mothers was analyzed for binding to B. pertussis, and 24 HC, 
21 LTR and 28 PERTUSSIS samples were tested against all other bacteria.
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fight infection by breast feeding. Milk IgA derives from plasma 
cells that migrate from mucosal sites to the mammary gland 
at the end of pregnancy and during lactation. IgA able to bind 
B. pertussis is increased in the milk of mothers not only of the 
pertussis group but also in LRTI mothers indicating that infec-
tions induce a wide spectrum reaction at mucosal sites. Here, 
both natural and specific IgA are found. Natural IgA, produced 
by a T-cell-independent mechanism in the absence of intentional 
immunization, plays a similar function of natural IgM in the 
serum (35, 36).
Natural IgM is produced by IgM memory B cells. Here, we 
show that IgM memory B cells secreting antibodies against PT, 
FHA, and PRN are significantly increased in the peripheral blood 
not only in the mothers of the pertussis children but also in the 
LRTI group. The aspecific increase in IgM memory B cells prob-
ably reflects the nature of this population.
We have proposed that IgM and switched memory B cells have 
separate functions during infection (14, 15). IgM memory B cells 
play the role of first-line protection, whereas switched memory 
B cells, generated by the specific immune response in the GCs, 
eliminate the pathogen and remain in the organism to prevent 
re-infection. The IgM memory response observed not only in the 
mothers of the PERTUSSIS group but also in those of the LRTI 
group confirms that IgM memory B  cells expand polyclonally 
as a first-line defense to infection. Accordingly, anti-PT-IgM 
increased in the serum of both PERTUSSIS and LRTI mothers. 
The increase in IgA in the milk of mothers of the PERTUSSIS and 
LRTI groups raises the question of whether polyclonal first-line 
reactions also occur at mucosal sites (35, 36).
Two important conclusions derive from our study, one con-
cerning the protection of the neonate and the second concerning 
the relative roles of pre-formed antibodies and memory B cells.
We show that unvaccinated mothers cannot protect their chil-
dren from pertussis because of the low levels of specific antibodies 
in the serum and breast milk. It is now clear that the best strategy 
to prevent the disease in infants is maternal vaccination during 
pregnancy. Acellular vaccines induce high levels of specific IgG 
in the serum of the mother, which will cross the placenta and 
9Marcellini et al. Pertussis Infection and Memory B Cells
Frontiers in Immunology | www.frontiersin.org September 2017 | Volume 8 | Article 1158
prevent infection of the child (31, 32). Maternal vaccination effec-
tively protects the neonate especially in the first two months after 
birth (32). The protective effects of maternal vaccination are not 
observed any more at 6 months of age (37). Passively transferred 
antibodies are highest in cord blood but rapidly decline and are 
much lower at two months of age (38), thus explaining the loss 
of the protective effect of maternal immunization on the infant.
Vaccine administration in pregnancy is safe for both mother 
and fetus. There is an interference of maternal IgG on the infant 
response to vaccination. A slight reduction of specific antibody 
titers in the children of immunized mothers has been observed 
after the first vaccine dose. The modest interference did not persist 
and disappeared after the following doses (39). Thus, maternal 
immunization does not impair the effectiveness of childhood 
vaccination. The optimal timing of vaccine administration during 
pregnancy has not yet been established. Third trimester vaccina-
tion results in high antibodies transfer to the neonate (39, 40), 
but second trimester vaccination is most effective for preterm 
neonates (41).
In our case–control study, based on serological data, we 
hypothesize that up to 50% of infants had probably been infected 
by the mother (18). If these mothers had been vaccinated in preg-
nancy, probably they would have not transmitted the disease and 
their children, having received high levels of maternal antibodies, 
would not have been hospitalized because of pertussis.
Several studies have started to address the issue of gender 
differences in the immune response and in immune-mediated 
diseases, demonstrating that the immune system of women is 
more active than that of men, responding better to infection, 
with the side effect of a higher incidence of autoimmune diseases 
(42, 43). The ability of women to produce more antibodies is 
useful for the survival of the species, because, in order to protect 
the neonate from infection in its first days and months of life, 
mothers donate to the child their antibodies of IgG and IgA type. 
This system is imperfect for pertussis and should be improved by 
maternal vaccination (44).
As PT is an important virulence factor for B. pertussis that 
damages the respiratory epithelium and impairs innate immune 
responses in the first few hours after infection, the low levels 
of pre-formed neutralizing antibodies explain why pertussis 
circulates notwithstanding the successfully implemented global 
vaccination strategies. On the other side, the mildness of the adult 
infection demonstrates that memory B cells are able to limit the 
damage and eliminate the pathogen. Memory B cells, generated 
by natural infection and vaccination, are indispensable for the 
rapid production of IgG antibodies during recall responses. There 
is no direct correlation between the number of memory B cells 
and the concentration of serum antibodies. In the case of hepa-
titis B vaccination, we have shown that memory B cells persist 
when antibodies decline below the protective threshold (45) and 
effectively respond to booster vaccine doses. Serum antibodies 
increase 3–7 days after triggering the recall response of memory 
B cells. For this reason when pre-formed serum antibodies are 
low, the ability of memory B cells to protect from an infectious 
disease depends on the nature of the pathogen (46). Hepatitis B 
has a slow pathogenesis, and memory B cells have enough time 
to differentiate into antibody secreting cells to ensure protection. 
In contrast, the pathogenesis of diseases caused by Neisseria 
meningitides, S. pneumoniae, and Haemophilus influenzae is so 
rapid (hours) that only pre-formed antibodies are able to protect 
the organism (46). Our results show that pertussis infection may 
be considered of intermediate pathogenicity, because memory 
B  cells avoid a severe disease in the adult, but are not able to 
prevent all symptoms and most importantly do not block disease 
transmission.
It has been suggested that pertussis vaccines may be improved 
by better preserving the native structure of the antigens used for 
immunization (47) and including adjuvants designed to potenti-
ate T-cell responses (48).
Our findings contribute to the discussion demonstrating that 
serum antibodies but not memory B cells are rapidly lost after 
natural infection. For this reason, more effective vaccines should 
also include adjuvants able to increase the number of specific 
long-lived plasma cells.
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FIGURE S1 | Description of the bacterial FACS method. (A) Colonies of bacterial 
isolates were diluted in FACS buffer and incubated either with FACS buffer or 
with maternal milk (1:10 and 1:30 dilutions). After washing, IgA bound to 
bacterial cells was revealed by a secondary staining with FITC-labeled mouse 
anti-human IgA. (B) Representative histograms showing the fluorescence of 
bacteria, without or with bound maternal IgA. (C) Relative representation of IgA 
binding to the indicated bacteria in the milk of healthy controls (HC), lower 
respiratory tract infections (LRTI), and PERTUSSIS mothers. As compared to  
B. pertussis, significantly higher amounts of antibodies bound to S. Aureus,  
S. salivarius, and S. pneumoniae in all of the three groups.
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